Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 May 2024
Molnupiravir for treating COVID-19 [ID6340]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 29 January 2025
Sipavibart for preventing COVID-19 [ID6282]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 26 February 2025
Ensitrelvir for treating COVID-19 [ID6231]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC